Abstract
Octreotide is a synthetic somatostatin analogue which has shown inhibitory activity against human breast cancer cells in culture. Ten patients with metastatic breast cancer and no prior hormonal therapy exposure received octreotide at 150 micrograms subcutaneously thrice daily. No objective responses were observed and the median time to treatment failure was short at 57 days.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Aged
-
Antineoplastic Agents, Hormonal / adverse effects
-
Antineoplastic Agents, Hormonal / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / pathology
-
Female
-
Humans
-
Middle Aged
-
Neoplasm Metastasis
-
Octreotide / adverse effects
-
Octreotide / therapeutic use*
-
Tamoxifen / administration & dosage
-
Tamoxifen / therapeutic use
Substances
-
Antineoplastic Agents, Hormonal
-
Tamoxifen
-
Octreotide